阿维鲁单抗联合阿昔替尼治疗易位性肾细胞癌：病例系列及文献综述
Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review.
作者信息
Takahashi Kenta, Kato Renpei, Ikarashi Daiki, Matsuura Tomohiko, Maekawa Shigekatsu, Kanehira Mitsugu, Takata Ryo, Sugimura Jun, Abe Takaya, Obara Wataru
机构信息
Department of Urology Iwate Medical University Shiwa-gun Iwate Japan.
出版信息
IJU Case Rep. 2023 Dec 27;7(2):131-135. doi: 10.1002/iju5.12685. eCollection 2024 Mar.
INTRODUCTION
Patients with translocation renal cell carcinoma (tRCC) have a poor prognosis without standardized treatment.
CASE PRESENTATION
The first case was of a 72-year-old woman who underwent robot-assisted partial nephrectomy for a left renal tumor and was pathologically diagnosed with tRCC. Recurrence was observed in the left retroperitoneal soft tissue. After treatment with avelumab-axitinib, continued progression-free survival was confirmed at the 90-week follow-up. The second case was of a 41-year-old woman referred to our hospital and presented with translocation renal cell carcinoma metastasis to a para-aortic lymph node. After treatment with avelumab-axitinib, continued progression-free survival was confirmed at the 43-week follow-up.
CONCLUSION
The outcomes of these cases indicate that avelumab-axitinib therapy has a long-term antitumor effect in some patients with tRCC.
引言
易位性肾细胞癌（tRCC）患者在没有标准化治疗的情况下预后较差。
病例报告
首例患者为一名72岁女性，因左肾肿瘤接受机器人辅助部分肾切除术，术后病理诊断为tRCC。在左腹膜后软组织中观察到复发。使用阿维鲁单抗-阿昔替尼治疗后，在90周随访时确认无进展生存期持续。第二例患者为一名41岁女性，转诊至我院，表现为tRCC转移至主动脉旁淋巴结。使用阿维鲁单抗-阿昔替尼治疗后，在43周随访时确认无进展生存期持续。
结论
这些病例的结果表明，阿维鲁单抗-阿昔替尼治疗对一些tRCC患者具有长期抗肿瘤作用。
Zotero 插件